2004

2004

Akkermansia muciniphila isolation, identification and characterization by Prof. W.M de Vos and his team – Wageningen University, The Netherlands

2008
2013

2008 2013

Collaboration between the teams of Prof. W.M. de Vos (Wageningen University) and Prof. P.D. Cani (UCLouvain) leading to the demonstration of the efficacy of Akkermansia muciniphila supplementation in the prevention of gut barrier dysfunction, obesity, diabetes and related metabolic disorders in preclinical models of obesity

2015

2015

Demonstration of the higher efficiency of the pasteurized Akkermansia muciniphila compared to the live bacterium in the prevention of gut barrier dysfunction, obesity, diabetes and related metabolic disorders in preclinical models of obesity

2016

Foundation of A-Mansia Biotech S.A. by Professors Patrice D. Cani and Willem M. de Vos

2016

2015

2015 2

First high-scale production of Akkermansia muciniphila at a quality level suitable for a clinical study and ethical committee approval for the Microbes4U study

microbes4u

2018

2018

Series A fundraising with Seventure and IFF as lead investors and SOPARTEC/Vives, SRIW and non-dilutive support from Walloon Region

2017

2017

Jean-Christophe Malrieu is appointed as CEO

2019

2019

Publication of the Microbes4U© study results in Nature Medicine : the first randomized double-blind placebo-controlled pilot study in human volunteers demonstrating that daily administration of pasteurized Akkermansia muciniphila for 3 months is safe, well tolerated and reduces cardiometabolic risk factors (pre-diabetes, hypercholesterolemia, low-grade inflammation)

2019

Application for the approval of pasteurised Akkermansia muciniphila as a novel food ingredient in the European Union

2019

2020

2020

Publication of the toxicological safety evaluation of pasteurized Akkermansia muciniphila